Prospective Episealer® Talus study 50% recruited
Episurf Medical (Nasdaq: EPIS B) today announces that 50% of the patients have been recruited to a prospective study on the Episealer Talus® implant, lead by Prof. Zaffagnini, from the Rizzoli Orthopaedic Institute in Bologna, Italy, supported by Dr Massimiliano Mosca. The study will follow 15 patients who received an Episealer Talus® implant as treatment for osteochondral defects in their ankle joint. Episealer® Talus is Episurf Medical’s CE marked implant technology, intended for the treatment of osteochondral ankle lesions. “This is an interesting technology, and we are happy to